Dietary excess triggers accumulation of pro-inflammatory microglia in the mediobasal hypothalamus (MBH), but the components of this microgliosis and its metabolic consequences remain uncertain. Here, we show that microglial inflammatory signaling determines the immunologic response of the MBH to dietary excess and regulates hypothalamic control of energy homeostasis in mice. Either pharmacologically depleting microglia or selectively restraining microglial NF-kB-dependent signaling sharply reduced microgliosis, an effect that includes prevention of MBH entry by bone-marrow-derived myeloid cells, and greatly limited diet-induced hyperphagia and weight gain. Conversely, forcing microglial activation through cell-specific deletion of the negative NF-kB regulator A20 induced spontaneous MBH microgliosis and cellular infiltration, reduced energy expenditure, and increased both food intake and weight gain even in absence of a dietary challenge. Thus, microglial inflammatory activation, stimulated by dietary excess, orchestrates a multicellular hypothalamic response that mediates obesity susceptibility, providing a mechanistic rationale for non-neuronal approaches to treat metabolic diseases.
In Brief
Whether the hypothalamic accumulation of activated microglia is a cause or a consequence of weight gain has been unclear. Valdearcos et al. show that microglia orchestrate a complex hypothalamic immune response to dietary excess and that microglial inflammatory signaling regulates both energy intake and expenditure; these cells and their signaling pathways could be targeted in obesity.
INTRODUCTION
Energy homeostasis depends on the integrated function of hypothalamic neurons that detect changes in nutrient availability through adiposity hormones, such as leptin, and coordinately control feeding behavior and metabolic rate (Schwartz et al., 2000) . However, the high prevalence of obesity indicates that environmental influences, such as dietary excess, can override this control system to promote weight gain.
Clear public health concerns have spurred efforts to determine how to maintain CNS control over energy balance in the face of dietary excess. While most studies have focused on hypothalamic neurons (Waterson and Horvath, 2015) , comparatively few have investigated non-neuronal cells, which outnumber neurons in the brain. Here, we provide the first mechanistic evidence that microglia, the self-renewing population of CNS macrophages, orchestrate both the immunologic and physiologic responses of the hypothalamus to dietary excess and instruct the hypothalamic control of food intake, energy expenditure, and body weight.
Diet-induced obesity (DIO) is associated with a form of lowgrade inflammation involving macrophages and other immune cells in white adipose and other metabolic tissues and is implicated in the development of insulin resistance (Gregor and Hotamisligil, 2011) . This process is paralleled by a more rapid response involving glial cell accumulation (gliosis) in the mediobasal hypothalamus (MBH), both in mice and humans (Buckman et al., 2013; Gao et al., 2014; Schur et al., 2015; Thaler et al., 2012; Valdearcos et al., 2014) , and the inflammatory activation of MBH microglia is prominent in the gliosis induced by highfat diet (HFD) or saturated fat consumption (Thaler et al., 2012; Valdearcos et al., 2014) . The porous blood-brain barrier (BBB) in the MBH may also allow infiltrating myeloid cells from the circulation to augment gliosis, as is seen in other CNS inflammatory conditions that alter BBB integrity (Ginhoux et al., 2010; Sheng et al., 2015) . However, because prior analyses of ''microgliosis'' in mice with DIO (e.g., Thaler et al., 2012; Valdearcos et al., 2014; Morari et al., 2014) used either common myeloid markers (e.g., Iba1, CD11b, Emr1) or methods that might damage the BBB (Buckman et al., 2014) , the identity of these immune cells remains uncertain.
The extent to which MBH microglial inflammatory activation regulates obesity pathogenesis also remains uncertain. On the whole, hypothalamic inflammation promotes overconsumption and weight gain in mice. For example, deleting or inhibiting the inflammatory master regulator NF-kB in neurons or astrocytes mitigated DIO while stimulating inflammation in the MBH impaired leptin and insulin signaling (Benzler et al., 2015; Douglass et al., 2017a; Zhang et al., 2008) . However, these studies have not addressed the potential role of microglia in this process. Indeed microglia can initiate and orchestrate processes that either exacerbate or protect against neurotoxicity, depending on the context (Aguzzi et al., 2013) . We showed that microglia mediate neuronal stress and leptin resistance due to saturated fat ingestion (Valdearcos et al., 2014) but have not yet explored their role in the more complex pathogenesis of obesity.
Here, we use multiple approaches to conditionally and specifically manipulate both the number and inflammatory activation state of resident microglia in mice. Attenuating microglial inflammatory capacity or depleting microglia altogether protects HFD-fed mice from hyperphagia and DIO and also mediates a striking reduction in microgliosis, in particular the elimination of MBH infiltration by bone-marrow-derived myeloid cells. By contrast, activating resident microglia is sufficient to trigger diet-independent weight gain and MBH recruitment of myeloid cells. Collectively, our results indicate that the inflammatory activation state of microglia controls the hypothalamic immune response to dietary excess and regulates the susceptibility to obesity.
RESULTS

Depleting CNS Resident Microglia Reduces Food Intake and Weight Gain in Mice Fed a HFD
To investigate the overall contribution of microglia to energy balance and obesity susceptibility, we fed mice either a control HFD or one containing the CSF1R inhibitor PLX5622 to selectively deplete microglia (Elmore et al., 2014) . Immunostaining for the microglial marker Iba1 revealed robust depletion of microglia in the MBH of PLX5622-treated mice, whether chronically fed a standard low-fat chow diet (CD) or a HFD ( Figures 1A and 1B) . By contrast, PLX5622 treatment did not deplete macrophages from the white adipose tissue (WAT) of the same mice, indicating relative microglial specificity ( Figure S1 ).
Depleting microglia significantly reduced weight gain in mice fed a HFD but not in mice fed a CD ( Figure 1C) . Similarly, PLX5622 treatment reduced total body fat (but not lean mass) ( Figure 1D ) and food intake only in HFD-fed mice (Figures 1E and 1F) . Together, these findings indicate that microglia help sustain caloric intake in the context of a HFD, thus driving increased adiposity and body weight.
Genetically Restraining the Inflammatory Responsiveness of Microglia Mitigates DIO
We sought to corroborate our findings from microglial depletion by using a genetic approach to specifically silence microglial NF-kBmediated inflammatory signaling. Mice expressing tamoxifeninducible Cre recombinase (CreER) in cells expressing CX3CR1 (CX3CR1 CreER/+ mice) were thus crossed with mice harboring conditional alleles of Ikbkb, which encodes IKKb, an essential cofactor for NF-kB activation (Ikbkb F/F ) (Li et al., 1999) . Treating the progeny with tamoxifen generated IKKb MGKO mice, in which Ikbkb is deleted in microglia ( Figure 2A ) and a subset of circulating myeloid cells ( Figure S2A ) (Jung et al., 2000) , and IKKb F/F controls.
Cre-mediated recombination is durable in microglia, which are long lived, but transient in peripheral CX3CR1 + cells, which are rapidly replaced by bone-marrow-derived precursors (Goldmann et al., 2013; Parkhurst et al., 2013 Figure 2D ), mirroring the effect of microglial depletion ( Figure 1C ). Similarly, microglial IKKb deficiency did not affect consumption of a CD ( Figure 2E ) but, like PLX5622 treatment, reduced cumulative intake of the HFD ( Figure 2F ). As before, reduced body fat accounted for the relative decrease in body weight (Figures 2G and 2H) . Both IKKb MGKO and control mice had similar rates of energy expenditure ( Figure 2I ), suggesting that reduced food intake is primarily responsible for the lean phenotype of IKKb MGKO mice. Finally, female IKKb MGKO mice were also resistant to DIO ( Figure S2 ). Next, we probed the impact of microglial IKKb deficiency on the ability of chronic dietary excess to produce microgliosis in the MBH. Compared to control mice, IKKb MGKO mice fed a HFD had consistently less microglial activation and accumulation, assessed by immunofluorescence to quantify microglial size and number (Figures 2J and 2K) . Together, these analyses indicate that microglial NF-kB-dependent signaling is necessary for HFD-induced hypothalamic microgliosis, hyperphagia, and DIO.
HFD-Responsive Microgliosis Occurs in an Anatomically
Specified Niche within the MBH To investigate the cellular composition of HFD-induced MBH microgliosis, we devised a multi-parameter immunofluorescence approach to stain MBH sections. Since the common microglial markers Iba1 and CX3CR1 are also expressed in some monocytes (CX3CR1), tissue macrophages (Iba1 and CX3CR1), and potentially perivascular CNS macrophages (CX3CR1) (Greter et al., 2015) , we added two specific markers, P2Y12 and Tmem119, that are expressed exclusively by microglia (Bennett et al., 2016; Butovsky et al., 2014) . Importantly, this approach also identifies the activation state of microglia, as microglial activation increases expression of Iba1 and reduces that of P2Y12 (Haynes et al., 2006) but does not alter Tmem119 or CX3CR1 levels. Therefore, using these four markers in combination assesses both the role of inflammation in HFD-induced MBH microgliosis and the cell types comprising this response.
We first confirmed that Iba1 + cells with an activated morphology accumulate in response to HFD consumption (4 weeks) in a cluster within the median eminence (ME) and ARC, but not the ventromedial hypothalamus (VMH; Figures 3A and 3B Figures 3C and 3D ). Indeed, typical double-positive resident microglia (CX3CR1 + /P2Y12 + or CX3CR1 + / Tmem119 + ) were rarely seen in the cluster of microgliosis within the MBH of mice fed a HFD. Rather, their frequency increased progressively from the ME to the VMH, and they remained morphologically quiescent when compared to the cells in the ARC and ME ( Figures 3C and 3D) . The MBH accumulation of Iba1-and CX3CR1-expressing cells lacking P2Y12 and Tmem119 in HFD-fed mice suggested the potential involvement of non-microglial myeloid cells in the gliosis response. Consistent with this hypothesis, HFD-fed mice had a significant rise in MBH cells expressing CD169 (Siglec1), which marks monocyte-derived cells, but not resident microglia (Butovsky et al., 2012; Gao et al., 2015) (Figures 3E and 3F ). (E) Equivalent food intake in IKKb MGKO and control mice fed a CD (n = 5-6).
(F) Reduced food intake in IKKb MGKO mice fed a HFD (cumulative intake normalized to intial body weight, n = 6-7; two-way RM-ANOVA; **p < 0.01, ***p < 0.001).
(G) Equivalent lean body mass in IKKb MGKO and control mice fed a CD and HFD (n = 10-12).
(H) Reduced total body fat in IKKb MGKO mice fed a HFD (n = 10-12/group; two-way ANOVA; *p < 0.05 KO HFD versus Ctl HFD). However, these CD169 + cells displayed a microglial morphology ( Figure 3E , inset), suggesting that they may assume a hybrid, microglia-like state on arrival in the niche. Since BrdU incorporation showed no evidence for HFD-induced proliferation of resident MBH microglia (data not shown), we explored the possibility that these atypical cells might indeed be recruited from the circulation.
Peripheral Myeloid Cells Are Prominent Participants in Diet-Induced Microgliosis
We used three separate strategies to define the contribution of infiltrating cells to hypothalamic microgliosis. First, we crossed CX3CR1
CreER/+ mice with Rosa26-lox-stop-lox-tdTomato mice (Gao et al., 2015) and treated the appropriate progeny with tamoxifen to label all CX3CR1-expressing cells, including microglia. After waiting 4 weeks for peripheral immune cell replacement by unlabeled bone-marrow-derived precursors, the mice were fed a CD or HFD for an additional 4 weeks. We saw that round, CCR2-expressing (RFP + ) cells reminiscent of monocytes appear in the MBH within a week of placing the mice on HFD ( Figure S3A ).
Finally, to definitively identify bone-marrow-derived cells, we lethally irradiated WT mice while shielding their heads and necks with lead to preserve BBB integrity (Mildner et al., 2007) and then performed bone marrow transplantation (BMT) with donor marrow from mice expressing ubiquitin-GFP (BMT GFP ) ( Figure 4D ). Following a 6-week recovery, we fed BMT GFP and control mice a CD or HFD for 4 weeks and then scored for the presence of GFP + cells in the MBH. Consistent with our prior approaches, the microgliosis induced in mice fed a HFD included a sharp increase in the number of GFP + (bone-marrow-derived)
cells (Figures 4E-4G and S3B).
To more specifically determine the cell types comprising HFDinduced microgliosis in BMT GFP mice, we performed combined immunohistochemistry for GFP, the microglia-specific marker Tmem119, and the pan-myeloid marker CD68 ( Figures 4E-4G ). The GFP + (bone-marrow-derived) cells in the MBH were always CD68 + , marking their myeloid origin, but never Tmem119 + , indicating that they are not typical resident microglia ( Figures  4E-4G ). These data together clearly indicate that HFD-induced microgliosis includes a prominent contribution from infiltrating bone-marrow-derived myeloid cells. We obtained essentially identical results when using P2Y12 to mark microglia ( Figures  S3C-S3E cells in CSF1R-eGFP (''MacGreen'') mice fed a control or PLX5622-containing CD for 3 weeks ( Figures S4C and S4D ). Except for a slight ($30%) reduction in non-classical (Ly6C Lo ) monocytes, PLX5622 treatment had no effect on the circulating GFP + pool, including neutrophils and monocyte subsets ( Figures  S4C and S4D ). These findings corroborate recent data indicating that PLX5622 treatment in mice did not lessen brain infiltration by circulating monocytes in response to systemic TNF treatment, indicating that it does not broadly deprive these cells of their chemotactic potential (Feng et al., 2017) .
We also corroborated our findings with PLX5622 by examining monocyte markers in IKKb MGKO mice. As expected, IKKb MGKO mice fed a HFD recruited fewer monocyte-derived (CD169 + ) cells into the MBH than did controls ( Figures 5B and 5D ). These models together indicate that resident microglial activation is required for diet-induced peripheral myeloid cell recruitment into the MBH.
Genetically Potentiating NF-kB-Dependent Inflammatory Activation in Microglia Increases DietInduced Hypothalamic Microgliosis We reasoned that if microglial inflammatory signaling mediates the impact of dietary excess on MBH neuronal function, then spontaneously activating microglia through genetic manipulation should be sufficient to drive both microgliosis and obesity in a diet-independent manner. To test this hypothesis, we targeted A20 (tumor necrosis factor alpha-induced protein 3 [TNFAIP3]), an anti-inflammatory molecule and primary negative regulator of NF-kB activity (Ma and Malynn, 2012) . A20-deficient mice spontaneously develop neuroinflammation, which has been attributed to A20 deficiency in microglia (Guedes et al., ) mice had an exaggerated TNF and IL-6 secretory response to LPS and saturated fatty acid (palmitate) treatments ( Figure S5A ). These findings suggested that mice lacking A20 specifically in microglia might have a heightened vulnerability to HFD-induced microgliosis and metabolic dysfunction.
To delete A20 specifically in microglia, we bred CX3CR1
CreER/+ mice with those expressing a conditional allele of A20 (Tnfaip3 F/F ) (A20 MGKO ). Treating primary microglia from A20 MGKO mice with 4-hydroxytamoxifen profoundly reduced Tnfaip3 mRNA levels ( Figure 6A ), resulting in increased basal and LPS-induced TNF and IL-6 secretion in vitro ( Figure 6B) .
Based on the hypersensitivity of A20-deficient microglia to inflammatory stimuli, we analyzed MBH microgliosis in a cohort of A20 MGKO and control mice fed a HFD beginning 4 weeks after tamoxifen administration. We first confirmed that, like IKKb MGKO mice, A20 MGKO mice maintained microglial A20 deletion at this time point, whereas gene expression in peripheral leukocytes had returned to WT status ( Figure S5B ). As predicted, A20 MGKO mice fed a HFD had a phenotype opposite to that of IKKb MGKO mice, displaying marked increases over control mice in the number and size of microglia in the MBH, indicated by Iba1 + cells bearing morphological features of inflammatory activation ( Figures 6C and 6D) . Moreover, the diet-induced MBH microglial accumulation in A20 MGKO mice included substantially more infiltrating CD169 + cells than in controls, a finding also opposite to the absence of these cells in IKKb MGKO mice ( Figures 6E and 6F) . Therefore, modulating the inflammatory activation potential of resident microglia in mice exerts reciprocal effects on microgliosis induced by HFD consumption in the MBH.
Interestingly, some CD169 + cells recruited to the MBH of HFD-fed A20 MGKO mice co-expressed Tmem119, confirming that these cells adopt features of resident microglia upon arrival in the niche ( Figures 6G and 6H) . Indeed, the robust MBH infiltration seen in HFD-fed A20 MGKO mice may have induced the entering cells to undergo a more complete microglial conversion, as the analogous cells in WT mice altered their morphology and expressed both Iba1 and CX3CR1 but did not express Tmem119 ( Figures 3E and 4E-4G ).
Microglial A20 Deletion Induces Diet-Independent Metabolic Dysfunction
The heightened inflammatory activation state of A20 MGKO microglia prompted us to hypothesize that A20 MGKO mice would have an intrinsic susceptibility to obesity. In testing this hypothesis, it was critical to avoid waiting for replacement of any circulating myeloid cells that had undergone tamoxifen-induced Cre-LoxP recombination. Therefore, we performed BMT on A20 MGKO and appropriate control mice using WT (Cre À ) donors, again employing head/neck shielding to preserve BBB integrity during irradiation ( Figure 7A ). After allowing time for bone marrow reconstitution, treating this model with tamoxifen deleted Tnfaip3 exclusively in microglia (A20 MGKO-BMT ). Using ubiquitin-GFP mice as BMT donors to monitor peripheral myeloid cell infiltration into the MBH, we found that tamoxifentreated A20 MGKO-BMT mice showed robust accumulation of GFP + cells in the MBH when fed only a CD ( Figure S6A ), indicating that microglial activation is sufficient on its own to recruit bone-marrow-derived myeloid cells into the MBH.
More impressively, the induction of microglial A20 deficiency in A20 MGKO-BMT mice induced a spontaneous and rapid 4-fold increase in body weight gain despite the mice being maintained on a CD ( Figure 7B ). This effect occurred during the first week after tamoxifen treatment and lessened over subsequent weeks. To determine the physiological mechanism for this weight gain, we analyzed energy balance in individually housed A20
MGKO-BMT and control mice using metabolic cages. Upon tamoxifen treatment, CD-fed A20 MGKO-BMT mice also had a 33% increase in ad libitum food intake over 4 days ( Figure 7C ) and concomitant reductions in VO 2 ( Figure S6B ), VCO 2 (Figure S6C ), and energy expenditure ( Figure 7E ) but no differences in respiratory exchange ratio (RER) ( Figure 7D ) or physical activity ( Figure S6D ) versus control mice. Corresponding with their lower metabolic rate, A20 MGKO-BMT mice had reduced mRNA levels of several thermogenic genes (e.g., Ucp1, Cidea) in the brown adipose tissue (BAT), with a similar trend seen in the WAT (Figure S6E ). These findings indicate that forcing microglial activation is sufficient to recapitulate key effects of HFD consumption on energy homeostasis. The relative hyperphagia seen in A20 MGKO-BMT mice prompted us to test their responsiveness to leptin, an important hormonal regulator of energy homeostasis. Just as chronic HFD consumption diminishes hypothalamic leptin signaling (El-Haschimi et al., 2000), deleting microglial A20 significantly reduced leptininduced STAT3 activation in MBH neurons, even in the absence of a dietary challenge ( Figures 7F and 7G ). This finding suggests that the inflammatory activation of microglia increases obesity susceptibility by reducing the sensitivity of MBH neurons to homeostatic signals such as leptin.
Microglial Inflammatory Signaling Does Not Directly Affect Glucose Homeostasis or Peripheral Inflammation
Our finding that microglial inflammatory signaling regulates obesity susceptibility prompted us to test whether it may also regulate glucose homeostasis. We analyzed glucose tolerance in IKKb MGKO and A20 MGKO-BMT mice ( Figures S7A and S7B ) at body weights equivalent to controls in order to avoid confounding by differential adiposity. Notably, the glucose tolerance of IKKb MGKO mice fed a HFD for 3 weeks and of A20 MGKO-BMT mice fed a CD for 3 weeks was similar to that of corresponding diet-matched, tamoxifen-treated controls ( Figures S7A and S7B ).
Given that obesity induces inflammation in peripheral metabolic tissues and that the brain can modulate peripheral immunity through autonomic pathways, including some potentially involving hypothalamic neurons (Matarese et al., 2013) , we tested whether microglial activation can produce peripheral inflammation. Comparing A20 MGKO-BMT and control mice fed a CD revealed no differences in the mRNA levels of inflammatory genes in the WAT or livers ( Figure S7C ) or in the circulating levels of TNF and IL-6 ( Figure S7D ). These results both underscore celltype specificity in the A20 MGKO-BMT model and confirm that microglial inflammatory activation is not sufficient to directly drive peripheral tissue or systemic inflammation. Similarly, measures of peripheral tissue and systemic inflammation were not different between HFD-fed IKKb MGKO and control mice when assessed before their body weights diverged (data not shown).
DISCUSSION
Microglia rapidly accumulate in the MBH of rodents fed a HFD. However, it was previously unclear whether gliosis is a reactive consequence of weight gain or whether non-neuronal cells are instead instructive, regulating energy balance and contributing to obesity pathogenesis. Here, we provide the first definitive evidence that microglia, through their capacity for inflammatory signaling, are critical regulators of the susceptibility to DIO and an essential conduit linking dietary overconsumption to hypothalamic dysfunction. We combine pharmacologic and genetic approaches to show that NF-kB-dependent microglial activation is critical for both the development of HFD-induced MBH microgliosis, including the ingress of bone-marrow-derived myeloid cells, and metabolic dysfunction. Restraining this inflammatory activation in mice, either by depleting microglia or by deleting microglial Ikbkb, reduces food intake, mitigates DIO, and prevents MBH infiltration. By contrast, genetically activating microglia is sufficient to induce diet-independent MBH microgliosis, myeloid cell infiltration, metabolic dysfunction, and obesity. Together, these findings identify microglia as central regulators of energy balance and suggest that manipulating their activation could be an effective therapeutic for metabolic pathologies including obesity.
Prior work deleting Ikbkb in neurons (pan-CNS or hypothalamus only) or disrupting CNS TLR4 signaling connected hypothalamic inflammation with leptin sensitivity and DIO in mice (Kleinridders et al., 2009; Milanski et al., 2012; Zhang et al., 2008) . Although these studies highlight the importance of neuronal inflammatory and/or stress signaling in DIO, the stimulus for this signaling remained unknown.
Emerging evidence suggests that non-neuronal cells may provide such a stimulus, linking diet to neuronal stress and consequent hypothalamic dysfunction (Douglass et al., 2017b; K€ alin et al., 2015; Valdearcos et al., 2015) . For example, we recently reported that astrocyte inflammatory signaling enhances established DIO (Douglass et al., 2017b) , but its role in initiating energy imbalance was not assessed. As for microglia, we showed that they are a prerequisite for lipid-induced hypothalamic inflammation and neuronal stress (Valdearcos et al., 2014) , and another recent study showed that NG2 glia maintain the dendritic processes of leptinergic neurons (Djogo et al., 2016) ; however, neither study reported on DIO. Here, using cell-specific mouse models, we establish that microglia not only sense pro-inflammatory signals associated with dietary excess, but also convey these signals in the MBH, modulating neuronal responsiveness to leptin and thus regulating energy homeostasis.
Whereas our findings point to a highly specialized interaction between microglia and neurons governing energy metabolism and associated behaviors, we found no weight-independent role for microglia in regulating glucose homeostasis or peripheral inflammation. These findings suggest that metabolic inflammation in peripheral tissues develops independently of the CNS, likely resulting from chronic nutrient overload and/or obesity itself. This finding may explain the slow progression of metabolic inflammation in peripheral tissues relative to the MBH and suggests the possibility of distinct sets of factors that mediate the ''metabolic'' activation of microglia versus peripheral macrophages.
How do activated microglia influence energy balance in the context of HFD feeding? Some insight may be gleaned from the features of A20 MGKO-BMT mice. In particular, increased food intake in A20 MGKO-BMT mice was associated with reduced leptin sensitivity by the MBH, and reduced whole-body energy expenditure was associated with a reduction in the mRNA levels of several thermogenic genes in the BAT, suggesting that microglial signaling may specifically interact with effector pathways of the sympathetic nervous system. However, the specific factors mediating such microglianeuronal cross-talk remain largely unknown. Candidate mechanisms include secreted cytokines (Guijarro et al., 2006) , cell-cell interactions (Suzumura, 2013) , modulation of tanycyte function (Balland et al., 2014) , and alterations to the integrity and selectivity of the BBB surrounding the MBH (Banks, 2006) . Additionally, A20 is involved in cell-type-specific processes beyond controlling NF-kB activity, including autophagy, aging, and cell death (Abbasi et al., 2015) . By further exploring A20 regulation of microglial function, we may uncover novel pathways and polarization states contributing to CNS metabolic regulation.
The mouse models we generated also provide important new insights into the cellular components of diet-induced microgliosis within the MBH. First, we note that the cluster of cells involved in this response is confined to the ARC and ME, whereas surrounding areas are devoid of such microgliosis. This anatomical specificity is intriguing, given that this region of the MBH is postulated to lie outside the traditional BBB (Olofsson et al., 2013) , allowing cells within it to sense and respond to circulating factors, and for circulating cells to extravasate from the vasculature and join in the response.
Second, HFD-induced microgliosis in the MBH largely involves cells lacking typical definitive microglial markers such as Tmem119 and P2Y12. Indeed, based on marker analysis, the number of resident microglia in the MBH decreased in mice fed a HFD. Coincidently, however, we saw a modest rise in the number of myeloid cells in the MBH expressing neither typical microglial markers nor markers indicative of a bloodborne origin. Though their identities remain uncertain, they may represent a non-microglial, yet long-lived, population of brainresident myeloid cells. Recently, for example, perivascular and meningeal macrophages were shown to have surprisingly slow turnover rates (Goldmann et al., 2016) . Indeed, some of these ''atypical'' CD68 + cells in the MBH of HFD-fed mice had morphologies suggestive of a perivascular origin, akin to cells seen at the edges of the MBH in CD-fed mice. Future work using appropriate models should attempt to define the specific contribution of perivascular and meningeal macrophages to diet-induced MBH microgliosis and hypothalamic function. Another possibility is that these cells are actually resident microglia that downregulate typical markers in response to inflammatory activation. P2Y12 expression, for example, declines with microglial activation (Haynes et al., 2006) , and many of the cells accumulating in the MBH in response to dietary excess had morphological features (shortened branches, enlarged cell bodies), suggesting cellular activation. If this were the case, then HFD-induced MBH microgliosis shifts the polarization of resident microglia but does not induce proliferation.
Whereas this conclusion is supported by our negative BrdU data, a recent study showed increased BrdU incorporation in the hypothalami of mice fed a HFD (André et al., 2017) . However, whereas diet-induced microgliosis is tightly confined to the MBH, the other study described BrdU incorporation outside of this region. Also, as only Iba1 was used to mark myeloid cells, it is unclear what specific cell types were involved in that reported proliferative response. Therefore, whereas the hypothalamic response to HFD consumption may include myeloid proliferation, our data indicate that MBH-resident microglia are not involved. Rather, our findings prompt interest in determining the transcriptional signature of HFD-activated MBH microglia and whether it is different from that induced by other stimuli and from that of microglia in other brain regions.
Third, our studies clearly reveal that myeloid cells leave the circulating pool and accumulate in the MBH of HFD-fed mice. Monocyte-derived macrophages infiltrate the brain in response to a variety of inflammatory stimuli, including mouse models of traumatic brain injury and peripheral surgical trauma, and microglia may generate the chemotactic signal driving such infiltration (Feng et al., 2016; Gao et al., 2015) . While prior work using bone marrow chimeras has suggested that hypothalamic infiltration by peripheral myeloid cells is also induced by HFD feeding for several months (Buckman et al., 2014; Morari et al., 2014) , these studies have been inconsistent (Baufeld et al., 2016) and confounded by the effects of irradiation on BBB integrity (Diserbo et al., 2002) . We overcame this potential confound in A20 MGKO-BMT mice by using lead head/neck shielding during irradiation. However, we also observed diet-induced MBH infiltration (CD169 + cells) in A20 MGKO mice, which never received irradiation or BMT. Future work should focus on determining what factors induce monocyte chemotaxis into the MBH in the context of dietary excess and the metabolic impact of blocking this process.
Upon entering the MBH, infiltrating myeloid cells display morphologies characteristic of resident microglia. The fate-switching capacity of peripheral monocytes was recently described (Varvel et al., 2012) , and future studies should determine its full extent in the MBH. On the other hand, this hybrid identity complicates studies to determine the independent impact of microglia versus infiltrating myeloid cells on metabolic regulation. For example, some of the GFP + myeloid cells infiltrating the MBH upon deleting microglial A20 coexpress Tmem119, normally a specific marker of resident microglia. This profound phenotypic conversion could have, in turn, acted to ameliorate the amplitude and kinetics of the inflammatory and metabolic responses initiated by tamoxifen treatment in A20 MGKO-BMT mice, especially given that the infiltrating cells expressed A20. Indeed, future work should determine whether infiltrating cells amplify MBH inflammation initiated by microglia or whether they function to quell this inflammation and hasten a return to homeostasis.
Our findings here begin to shed light on this question; it is remarkable that either treating mice with PLX5622 or deleting Ikbkb in microglia reduces DIO susceptibility in conjunction with abrogating peripheral cell infiltration into the MBH, whereas microglial A20 deficiency induces both metabolic dysfunction and the influx of peripheral myeloid cells into the MBH. This tight correlation between metabolic outcomes and cellular infiltration suggests that myeloid cells drawn to the MBH may indeed contribute to the pathogenesis of DIO, a hypothesis that awaits the molecular tools to independently manipulate different subtypes of myeloid cells.
In conclusion, we identify microglia as critical regulators of the hypothalamic control of energy balance and validate the concept of targeting microglia to treat obesity. In this light, it is notable that a CSF1R inhibitor highly related to PLX5622 (PLX3397) is currently being tested in human cancer trials (https://clinicaltrials.gov), potentially providing data on body weight effects in human subjects. In addition to cell depletion strategies, future therapeutics that functionally modulate microglia could offer new approaches to control energy balance and mitigate obesity and its pathologic consequences.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
ACKNOWLEDGMENTS
We thank Plexxikon and Dr. Brian West for PLX5622. This work was supported by the American Diabetes Association (Pathway Award 1-14-ACE-51 to J.P.T.), the NIDDK (K08 DK088872 to J.P.T., T32 DK7247-37 and F32 DK108473-01 to J.D.D., and R01 DK103175-02 to S.K.K.), and a UCSF Diabetes Family Fund Award to M.V. Metabolic phenotyping was assisted by the Nutrition Obesity Research Centers at UCSF (DK098722) and The University of Washington (DK035816), and the Diabetes Research Center at The University of Washington (DK017047). 
STAR+METHODS KEY RESOURCES TABLE CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Suneil K. Koliwad (skoliwad@diabetes.ucsf.edu) .
EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
All studies used male C57BL/6 background mice, although we also analyzed female mice lacking microglial IKKb in order to validate the sex-selectivity of the phenotypes in question. Mice were 8 weeks old when irradiated for bone marrow transplantation, were between 8-12 weeks old when treated with tamoxifen, and were subsequently analyzed over a period of 3 days to 12 weeks while other regions, embedded in optimal cutting temperature compound, immediately frozen on dry ice, and stored at À80 C. Next, 35-mM-thick hypothalamic coronal sections were cut on a cryostat, blocked for 1 hr with 5% BSA in PBS containing 0.1% Triton X-100, and incubated with primary antibodies overnight at 4 C. Primary anti-mouse antibodies were against Iba1 (1:500 rabbit polyclonal; Wako), P2y12 (1:1000, kindly provided by Dr. David Julius), Tmem119 (1:500, kindly provided by Dr. Ben Barres), CD169 (1:300 rat polyclonal, Bio-rad), GFP (1:300 chicken polyclonal, Aves Labs), tdTomato/RFP (1:500 rabbit polyclonal, Rockland), CD68 (1:500 rat polyclonal, AbD serotec) and pSTAT3 (1:200, Cell Signaling). Epididymal white adipose tissue staining was done using the whole-mount technique as described (Martinez-Santibañ ez et al., 2014) with primary antibodies against caveolin-1 (1:500 rabbit polyclonal, BD BioScience) and F4/80 (1:300 rat polyclonal, Abcam). Adequate AlexaFluor-conjugated secondary antibodies were used for immunofluorescence microscopy. Sections were mounted with DAPI Vectashield solution (Vector Laboratories) to identify cell nuclei. The HRP-diaminobenzidine reaction was performed with the ABC Kit (Vector Laboratories), using biotin-labeled goat antirabbit IgG. Images were acquired with a confocal laser-scanning microscope (Leica TCS SP5) and Zeiss AxioImager brightfield microscope.
Cell Counting and Cell Size Determination Iba1 + cells were counted manually from matched sections within prespecified regions of interest using ImageJ software. Microglial cell size was determined using a thresholding protocol (ImageJ) followed by densitometric quantification. pSTAT3-positive cells were counted from matched sections between Bregma À1.22 to À2.30 (Paxinos Mouse Brain Atlas). To determine the number of pSTAT3-positive cells in the ARC, the threshold was defined as the intensity where cells are clearly pSTAT3-positive by visual inspection.
Flow Cytometry and Cell Sorting
Blood was collected in EDTA tubes via facial vein bleed from live mice. Whole blood was stained with fluorochrome-conjugated antibodies and treated with Ammonium-Chloride-Potassium to lyse red blood cells. Cell pellets were resuspended with FACS buffer (BD bioscience), blocked (FcBlock; BD Biosciences) for 30 min, and stained (30 min) with Ly6C-PerCP/Cy5.5 (Biolegend, clone HK1.4) and Ly6G-APC (eBioscience, clone 1A8-Ly6g). CSF1R-expressing (GFP + ) cells in MacGreen mice were gated for viability (PI). Data were acquired on a BD LSR II flow cytometer (BD Biosciences) using ''Fluorescence minus one'' controls to set up gates. Data were analyzed by FlowJo v10 software (Tree Star). IKKb MGKO mice were validated by collecting tail blood from adult
Cx3cr1
CreER-EYFP/+ :Ikbkb F/F mice before and after (1 and 4 wks) TAM administration. After red blood cell lysis, eYFP + monocytes were sorted by a FACSAria II (Becton Dickinson) and gated for viability (DAPI). IKKb mRNA levels were measured in sorted cells by RT-qPCR.
Real-Time Quantitative PCR Total RNA was extracted using Trizol or RNeasy micro kit according to manufacturers' instructions (QIAGEN) and reverse-transcribed with High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Transcript levels were measured by semiquantitative real-time PCR on an ABI Prism 7900 HT (Applied Biosystems) machine and SYBR green detection of amplicons. Data was analyzed using the sequence detection system software (SDS version 2.2; Applied Biosystems) and relative mRNA abundance was normalized to 18S. Primer sequences are listed in Table S1 .
Cytokine and Chemokine Measurements TNF and IL6 levels were measured in primary culture media by ELISA kits (eBioscience) according to the manufacturer's instructions.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are presented as mean ± SEM. Two groups were compared by unpaired two-tail Student's t test. For more than two groups, one-or two-way ANOVA was used, as appropriate, followed by Bonferroni post hoc adjustment. Repeated-measures ANOVA (RM-ANOVA) was also used whenever appropriate. All analyses used GraphPad software. p < 0.05 was considered significant.
